Trials / Terminated
TerminatedNCT05839509
Phase 2 Clinical Trial of GH001 in Bipolar II Disorder
A Phase 2 Clinical Trial of GH001 in Patients with Bipolar II Disorder and a Current Major Depressive Episode
- Status
- Terminated
- Phase
- Phase 2
- Study type
- Interventional
- Enrollment
- 6 (actual)
- Sponsor
- GH Research Ireland Limited · Industry
- Sex
- All
- Age
- 18 Years – 64 Years
- Healthy volunteers
- Not accepted
Summary
This study is a multicenter, open-label, single-arm Phase 2 clinical trial. Approximately 15 participants with clinically diagnosed bipolar disorder (BD) type II and experiencing a current episode of depression will be included in this study. The participants will receive an individualized dosing regimen (IDR) with at least one and up to three doses of GH001 administered within a single day.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | GH001 | GH001 administered via inhalation |
Timeline
- Start date
- 2023-04-06
- Primary completion
- 2024-11-13
- Completion
- 2024-12-05
- First posted
- 2023-05-03
- Last updated
- 2025-02-18
Locations
7 sites across 3 countries: Germany, Netherlands, United Kingdom
Source: ClinicalTrials.gov record NCT05839509. Inclusion in this directory is not an endorsement.